type 2 diabetes
Conditions
Interventions
lixisenatide administration periods:more than 10 days dose:15~20ug the number of times:once a day before breakfast
liraglutide administration periods:more than 10 days dose:0.6~0.9mg the num
Sponsors
University of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic patients being in hospital for the purpose of intensive insulin therapy including long-acting insulin. (Fasting CPR>0.6ng/ml, total bolus insulin <15units/day)
Exclusion criteria
Exclusion criteria: Patients with type 1 diabetes, patients with severe hypoglycemia, patients with severe liver disease, patients with severe renal disease, patients with severe heart disease, patients with history of myocardial infarction within 6 months, patients with severe pancreatic disease, cancer patients, patients with severe diabetic neuropathy, patients with severe diabetic retinopathy, patients with severe ketosis and in a coma, patients with history of digestive diseases, patients with history of gastrectomy, patients with lactose intolerance, heavy drinkers, patients using steroid, pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MAGE(Mean amplitude of glycemic excursion) of more than 10 days after thrapeutic intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| data in CGM (mean blood glucose, SD, pre-meal plasma glucose in point of care testing, M-value, hypoglycemic index), fasting plasma glucose, 1 hour post prandial glucose, 2 hour post prandial glucose, lipid profile, blood pressure, heart rate, side effect | — |
Countries
Japan
Contacts
Public ContactMichiko Imagawa
University of Fukui Division of Endocrinology and Metabolism, Department of Internal medicine
Outcome results
None listed